PHASE II RANDOMIZED TRIAL OF OPTIMAL RECURRENCE-DIRECTED THERAPY (RDT) WITHOUT OR WITH ANDROGEN-DEPRIVATION THERAPY (ADT) IN RADIO-RECURRENT OLIGO-METASTATIC HORMONE/CASTRATE SENSITIVE PROSTATE CANCER (ROMCSPC): THE OCOG-RATIONAL-PCS TRIAL
Conferences